Search Results

Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced a number of updates pertaining to the advancement of universal newborn screening for metachromatic leukodystrophy.

Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced four oral and four poster presentations from across its hematopoietic stem cell gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy taking place May 7-11, 2024, in Baltimore.

Kyowa Kirin Co., Ltd. a Japan-based global specialty pharmaceutical company discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc, a global gene therapy leader, announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics.

Kyowa Kirin Co., Ltd. and Orchard Therapeutics plc announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics for $16.00 per American Depositary Share in cash, under which Orchard shareholders will hold an additional contingent value right of $1.00 per ADS.

Orchard Therapeutics today announced the details of its U.S. commercial launch of Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200.

Orchard Therapeutics today announced 10 presentations from across its neurometabolic portfolio will be featured at the 20th Annual WORLD Symposium™ taking place February 4-9, 2024, in San Diego, California.

Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.

Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy ® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD).